Globus Medical Acquires Nevro for $250 Million

Globus Medical (GMED) entered a merger agreement on February 6, 2025, to acquire Nevro Corp. (NVRO) in an all-cash deal valued at $250 million.

Deal Structure:

As per the terms of the agreement, Globus Medical will acquire all shares of Nevro for $5.85 per share, representing a 16.53% premium from the stock’s last close.

Company Profile:

Nevro is a global medical device company based in Redwood City, California, specializing in innovative solutions for chronic pain, including its HFX spinal cord stimulation platform and minimally invasive treatments for sacroiliac joint pain.

Globus Medical is a global musculoskeletal company based in Audubon, Pennsylvania, developing medical devices and solutions for spine, orthopedic trauma, joint reconstruction, and enabling technologies to address musculoskeletal disorders.

Deal Details and Timeline:

“This transaction furthers our mission to become the preeminent musculoskeletal technology company in the world by enabling us to expand into new markets for future growth,” said Dan Scavilla, CEO of Globus Medical.

Following the completion of the transaction, expected in the late second quarter of 2025, Globus Medical projects 2025 net sales of $2.8 to $2.9 billion and non-GAAP earnings per share of $3.10 to $3.40. The Nevro acquisition is anticipated to boost earnings in its second year.

In this transaction, BofA Securities served as financial advisor and Latham & Watkins provided legal counsel to Nevro. Morgan Stanley acted as financial advisor and Wyrick Robbins Yates & Ponton served as legal counsel to Globus Medical.

Globus Medical is acquiring Nevro at 0.44 times its sales.

Deal Metrics:

For a more comprehensive examination of this M&A deal, please visit the Deal Metrics page at:

Deal Metrics for the acquisition of Nevro Corp. (NVRO) by Globus Medical (GMED)

The Deal Metrics page for each merger or acquisition includes:

• A spread history chart of the merger from announcement to completion or failure.
• Track every event as the merger advances through HSR period expiration, various regulatory approvals, shareholder votes, etc.
• Latest news and SEC filings.
• A history of deal updates.
• And much more.

Disclaimer: Please conduct your own due diligence prior to buying or selling any securities mentioned in this article. We do not guarantee the completeness or accuracy of the content or data provided in this article.

Editor’s Note: Baranjot Kaur contributed to this article